Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
NCT02784444 is registered in ClinicalTrials.gov with Cirius Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
- Lead sponsor
- Cirius Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 14, 2016
- Completion date
- June 30, 2019
- Enrollment
- 392 (actual)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.
nash - nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis